Drug Profile
AMY 101
Alternative Names: AMY101Latest Information Update: 20 Dec 2022
Price :
$50
*
At a glance
- Originator University of Pennsylvania
- Developer Amyndas Pharmaceuticals
- Class Anti-inflammatories; Antianaemics; Eye disorder therapies; Peptides; Proteins; Uroprotectives
- Mechanism of Action Complement C3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Gingivitis; Periodontitis; SARS-CoV-2 acute respiratory disease
- Phase I Membranous glomerulonephritis; Paroxysmal nocturnal haemoglobinuria; Renal transplant rejection
- Discontinued Age-related macular degeneration; Renal failure
Most Recent Events
- 20 Dec 2022 Amyndas Pharmaceuticals plans a phase II trial for Membranous glomerulonephritis (Amyndas pharmaceuticals pipeline, December 2022)
- 20 Dec 2022 Amyndas Pharmaceuticals plans a phase II trial for Paroxysmal nocturnal haemoglobinuria (Amyndas Pharmaceuticals pipeline, December 2022)
- 22 Sep 2022 Discontinued - Phase-I for Age-related macular degeneration (In volunteers) in USA (IV) (Amyndas pipeline, September 2022)